Trilaciclib May Reduce Single, High-Grade Myelosuppression in ES‑SCLC
Treatment with trilaciclib (Cosela) may limit single and multilineage grade 3 or higher myelosuppressive hematologic adverse effects (HAEs) and cytopenia related to health‑care utilization in patients with extensive‑stage small‑cell lung cancer (ES‑SCLC).
Real‑world evidence indicates that trilaciclib (Cosela) reduces grade 3 or higher myelosuppressive hematologic adverse events (HAEs) and associated cytopenia‑related healthcare utilization in patients with extensive‑stage small‑cell lung cancer (ES‑SCLC).
The reduction of severe myelosuppression may improve patients’ clinical outcomes, reduce dose reductions and treatment delays, and lower healthcare resource utilization, potentially translating into better survival and quality of life for those with extensive‑stage SCLC.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells